CD8 T-cell Immune Escape by SARS-CoV-2 Variants of Concern

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 17

PMID 36389664

Authors

Arnaud John Kombe Kombe

Fleury Augustin Nsole Biteghe

Zelia Nelly Ndoutoume

Tengchuan Jin

Affiliations

Soon will be listed here.

Abstract

Despite the efficacy of antiviral drug repositioning, convalescent plasma (CP), and the currently available vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the worldwide coronavirus disease 2019 (COVID-19) pandemic is still challenging because of the ongoing emergence of certain new SARS-CoV-2 strains known as variants of concern (VOCs). Mutations occurring within the viral genome, characterized by these new emerging VOCs, confer on them the ability to efficiently resist and escape natural and vaccine-induced humoral and cellular immune responses. Consequently, these VOCs have enhanced infectivity, increasing their stable spread in a given population with an important fatality rate. While the humoral immune escape process is well documented, the evasion mechanisms of VOCs from cellular immunity are not well elaborated. In this review, we discussed how SARS-CoV-2 VOCs adapt inside host cells and escape anti-COVID-19 cellular immunity, focusing on the effect of specific SARS-CoV-2 mutations in hampering the activation of CD8 T-cell immunity.

Citing Articles

The trend of phylogenetic and epitope variations of SARS-CoV-2 Omicron sub-lineages in Iran.

Shabani M, Nejati A, Yavarian J, Sadeghi K, Zadheidar S, Ahmadi A Front Microbiol. 2025; 15:1531712.

PMID: 39943963 PMC: 11815659. DOI: 10.3389/fmicb.2024.1531712.

The role of inflammatory gene polymorphisms in severe COVID-19: a review.

Yip J, Oo A, Ng Y, Chin K, Tan K, Chu J Virol J. 2024; 21(1):327.

PMID: 39707400 PMC: 11662554. DOI: 10.1186/s12985-024-02597-3.

Features of Highly Homologous T-Cell Receptor Repertoire in the Immune Response to Mutations in Immunogenic Epitopes.

Zornikova K, Dianov D, Ivanova N, Davydova V, Nenasheva T, Fefelova E Int J Mol Sci. 2024; 25(23).

PMID: 39684303 PMC: 11641755. DOI: 10.3390/ijms252312591.

SARS-CoV-2 within-host population expansion, diversification and adaptation in zoo tigers, lions and hyenas.

Bashor L, Gallichotte E, Galvan M, Erbeck K, Croft L, Stache K bioRxiv. 2024; .

PMID: 39484504 PMC: 11527109. DOI: 10.1101/2024.10.24.620075.

The molecular mechanisms of CD8 T cell responses to SARS-CoV-2 infection mediated by TCR-pMHC interactions.

Deng S, Xu Z, Hu J, Yang Y, Zhu F, Liu Z Front Immunol. 2024; 15:1468456.

PMID: 39450171 PMC: 11499136. DOI: 10.3389/fimmu.2024.1468456.

References

Tan Y, Schneider T, Leong M, Aravind L, Zhang D . Novel Immunoglobulin Domain Proteins Provide Insights into Evolution and Pathogenesis of SARS-CoV-2-Related Viruses. mBio. 2020; 11(3). PMC: 7267882. DOI: 10.1128/mBio.00760-20. View

Pereira F . SARS-CoV-2 variants combining spike mutations and the absence of ORF8 may be more transmissible and require close monitoring. Biochem Biophys Res Commun. 2021; 550:8-14. PMC: 7906533. DOI: 10.1016/j.bbrc.2021.02.080. View

Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H . Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475-481. PMC: 7102538. DOI: 10.1016/S2213-2600(20)30079-5. View

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L . Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2008; 13(10):1562-4. PMC: 2851497. DOI: 10.3201/eid1310.070576. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

O Murchu E, Byrne P, Carty P, De Gascun C, Keogan M, ONeill M . Quantifying the risk of SARS-CoV-2 reinfection over time. Rev Med Virol. 2021; 32(1):e2260. PMC: 8209951. DOI: 10.1002/rmv.2260. View

Callaway E . Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887):21. DOI: 10.1038/d41586-021-03552-w. View

Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi J . Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020; 9. PMC: 7723407. DOI: 10.7554/eLife.61312. View

Bert N, Tan A, Kunasegaran K, Tham C, Hafezi M, Chia A . SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020; 584(7821):457-462. DOI: 10.1038/s41586-020-2550-z. View

10.

Pacha O, Sallman M, Evans S . COVID-19: a case for inhibiting IL-17?. Nat Rev Immunol. 2020; 20(6):345-346. PMC: 7194244. DOI: 10.1038/s41577-020-0328-z. View

11.

Wu Y, Guo C, Tang L, Hong Z, Zhou J, Dong X . Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol. 2020; 5(5):434-435. PMC: 7158584. DOI: 10.1016/S2468-1253(20)30083-2. View

12.

Tang F, Quan Y, Xin Z, Wrammert J, Ma M, Lv H . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011; 186(12):7264-8. DOI: 10.4049/jimmunol.0903490. View

13.

Garcia-Beltran W, Lam E, St Denis K, Nitido A, Garcia Z, Hauser B . Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell. 2021; 184(9):2372-2383.e9. PMC: 7953441. DOI: 10.1016/j.cell.2021.03.013. View

14.

Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y . Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2. J Hum Genet. 2020; 65(7):569-575. PMC: 7200206. DOI: 10.1038/s10038-020-0771-5. View

15.

Agerer B, Koblischke M, Gudipati V, Montano-Gutierrez L, Smyth M, Popa A . SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 T cell responses. Sci Immunol. 2021; 6(57). PMC: 8224398. DOI: 10.1126/sciimmunol.abg6461. View

16.

Lin L, Lu L, Cao W, Li T . Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020; 9(1):727-732. PMC: 7170333. DOI: 10.1080/22221751.2020.1746199. View

17.

Chen J, Wang R, Gilby N, Wei G . Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance. J Chem Inf Model. 2022; 62(2):412-422. PMC: 8751645. DOI: 10.1021/acs.jcim.1c01451. View

18.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

19.

Cox A, Mosbruger T, Mao Q, Liu Z, Wang X, Yang H . Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med. 2005; 201(11):1741-52. PMC: 2213263. DOI: 10.1084/jem.20050121. View

20.

Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View